NXGL: NEXGEL Company Total Sales

Proprietary sterile hydrogel cross-linking technology provides NEXGEL, Inc. (NXGL) with a sustainable advantage. The company's sales profile demonstrates growth driven by the implementation of transdermal drug delivery systems and the expansion of the OTC segment. Revenue scaling is supported by B2B partnerships for patch production. The current 0.01 metric confirms the level of operational maturity of the business, which is clearly reflected in the chart's price action.

NEXGEL, Inc (NXGL) - Company Sales from 07/04/2022 to 11/14/2026

Comprehensive metric breakdowns and analytics for NEXGEL (NXGL)

- market value and analyst target forecast:

Market Chart NEXGEL Inc|NXGL - Consensus Target

- market capitalization information:

Market Value NEXGEL, Inc.|NXGL - Total Company Value

- book capitalization indicators:

Accounting Value of a Share NEXGEL|NXGL - Company Net Assets|Market Capitalization to Book Value Ratio nexgel.com|NXGL - Aggregate Company Assets

- company liabilities and liquidity data:

- earnings and valuation multiples indicators:

NXGL - Company Net Income|Net Profit Forecast NEXGEL, Inc.|NXGL - P/E Multiple|Projected Price to Earnings Ratio nexgel.com|NXGL - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation NEXGEL, Inc.|NXGL - Operating profit EBITDA|Net earnings per share for the trailing year NEXGEL|NXGL - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months nexgel.com|NXGL - Earnings per share growth in current year|Net earnings per share growth forecast for next year NEXGEL, Inc.

- issuer revenue and sales details:

NXGL - Company Sales|Company Future Revenue NEXGEL Inc|NXGL - P/S Multiple|Market Cap to Expected Sales Ratio NEXGEL, Inc.

Comprehensive company analysis:NEXGEL Inc NXGL

To assess business resilience, I analyze the total daily product revenue to determine operational intensity. This metric captures real cash flow volumes, allowing investors to filter out market noise from actual operations. By analyzing the sales performance of NEXGEL, Inc. (NXGL), one can confirm the efficiency of its B2B contract manufacturing model for hydrogels. Specializing in custom orders protects NEXGEL, Inc. (NXGL) from consumer market volatility.

Competing companies